Clinical trials: Psychoses
Schizophrenia
A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses
To evaluate the pharmacokinetics (PK), tolerability, and safety of brexpiprazole QW formulation administered as single and multiple doses in patients with schizophrenia.
- Trial name
- NCT04118127
- Testing
- 2mg conventional tablet, once-weekly tablets
- Where
- Japan
- Volunteers
- 73 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia is a brain disease. The condition may be associated with acute psychotic episodes and long-term disability despite remission from the acute symptoms.
- Trial name
- NCT00150176
- Testing
- Asenapine - Open Label, Asenapine - Double Blind
- Volunteers
- 831 people
- Sponsor
- Organon and Co
Schizophrenia, Schizoaffective Disorder
Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone
The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory…
- Trial name
- NCT00406315
- Testing
- ziprasidone
- Where
- 40 sites in United States, Brazil and 4 more
- Volunteers
- 255 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.
- Trial name
- NCT00176423
- Testing
- galantamine
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Maryland, Baltimore
Mental Disorder
Do Consumer Providers Enhance Recovery?
Serious mental illness (SMI) is the second most costly disorder treated in the VHA, yet clinical outcomes for these patients in public sector settings are often poor due to a combination of low quality care and severe cognitive…
- Trial name
- PEER (NCT00781079)
- Testing
- Consumer Provider
- Where
- 7 sites in United States
- Volunteers
- 285 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Improving Cognition in Schizophrenia Using tDCS
This study will examine the benefits of transcranial direct current stimulation (tDCS), a new tool that is being developed as a safe and non-invasive neurostimulation method, for improving neurocognitive and social cognitive…
- Trial name
- ICDC (NCT02539797)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo.
- Trial name
- NCT00615433
- Testing
- Lurasidone, Olanzapine, Lurasidone 40 mg tablets
- Where
- 52 sites in United States, Colombia and 3 more
- Volunteers
- 478 people
- Sponsor
- Sumitomo Pharma America, Inc.
Psychotic Disorders, Schizophrenia
A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness
This is a prospective study using a concierge model of customized adherence enhancement and long-acting injectable antipsychotic (CAL-Concierge) in 30 individuals with schizophrenia or schizoaffective disorder at risk for…
- Conditions
- Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Medication Adherence
- Trial name
- CAL-C (NCT02085447)
- Testing
- CAE-L
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Psychotic Disorders
Mobile After-Care Intervention to Support Post-Hospital Transition (MACS)
This study examines the feasibility and acceptability of a mobile device-delivered app, called Mobile After-Care Support (MACS), to improve patients' coping and treatment adherence following a hospitalization related to their…
- Trial name
- MACS (NCT03769493)
- Testing
- Mobile After-Care Support (MACS) app
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Butler Hospital
Schizophrenia
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
- Trial name
- COATS (NCT00802100)
- Testing
- Olanzapine, Perphenazine, Aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers
This study will determine whether using a pager improves medication adherence in people with schizophrenia.
- Trial name
- NCT00392236
- Testing
- 2-way pager, Treatment as usual
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Sulforaphane to Reduce Symptoms of Schizophrenia
The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
- Trial name
- NCT02810964
- Testing
- Sulforaphane Nutraceutical
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia, Schizoaffective Disorder
A Definitive Estrogen Patch Study (ADEPT)
OBJECTIVE: To test the use of adjunctive estrogen in a 8 week, three-arm, double-blind, placebo-controlled study in the treatment of psychotic symptoms in women with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder(Not in Manic Phase)
- Trial name
- NCT00357006
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- The Alfred
Schizophrenia, Metabolic Syndrome X
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with…
- Conditions
- Schizophrenia, Metabolic Syndrome X, Insulin Resistance
- Trial name
- NCT00338949
- Testing
- Switch, Control
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Veterans Medical Research Foundation
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Schizophrenia
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of once weekly dosing of zicronapine, compared to daily dosing of zicronapine.
- Trial name
- NCT01377233
- Testing
- Zicronapine open-label lead-in 10 mg daily, Zicronapine 10 mg daily, Zicronapine 20 mg once weekly
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia; Psychosis
Pharmacological Modulation of Hippocampal Activity in Psychosis 2
The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity in people with psychotic disorders.
- Trial name
- NCT04559529
- Testing
- Levetiracetam (LEV) 500 mg
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Psychosis, Substance Abuse
Effect Evaluation of Individual Placement and Support (IPS)
Roughly one third of disability pensions issued in Norway are classified as mental and behavioral disorders. The proposed study aims to evaluate the effect of an innovative intervention for returning people with moderate to…
- Conditions
- Psychosis, Substance Abuse, Depression, Anxiety
- Trial name
- NCT01964092
- Testing
- Individual Placement and Support, Ordinary employment schemes
- Where
- Norway
- Volunteers
- 410 people
- Sponsor
- NORCE Norwegian Research Centre AS
Schizophrenia, Schizoaffective Disorder
Biomarkers in Schizophrenia
N-methyl-D-aspartate (NMDA)-type glutamate receptors are thought to play a pivotal role in neurocognitive dysfunction associated with schizophrenia.
- Trial name
- NCT00817336
- Testing
- D Serine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
A Multicenter Study of NAP (AL-108) in Schizophrenia
The TURNS is a NIMH-funded contract for the evaluation of new compounds for the treatment of cognitive impairments in schizophrenia (HHSN 27820044 1003C; P.I.: Steve Marder, M.D.).
- Trial name
- AL-108 (NCT00505765)
- Testing
- AL-108
- Where
- 8 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of California, Los Angeles